Ileal bile acid transporter inhibitors
Journal of Pediatric Gastroenterology and Nutrition · 17.11.2026
DOI: 10.1002/jpn3.70692 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 17.11.2026. Verfasst von Ersilia Di Buduo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento Interdisciplinare di Medicina, Università degli Studi Di Bari, Bari, Italy. Die Arbeit nennt 15 Literaturangaben. Gefördert von: Ministero della Salute, Piano Sviluppo e Coesione Salute - FSC 2014-2020 - Traiettoria 3, Incentivi Fondo per lo sviluppo di tecnologie e applicazioni di intelligenza artificiale, blockchain e Internet of Things, European Union-Next Generation EU-PNRR M6C2.
Abstract (Originalsprache)
Pediatric cholestatic liver diseases, such as Alagille syndrome and progressive familial intrahepatic cholestasis, are rare genetic disorders characterized by impaired bile flow, systemic bile acid accumulation, and debilitating pruritus. Historically managed with supportive care or invasive surgical interventions, the therapeutic landscape has recently expanded with the introduction of ileal bile acid transporter (IBAT) inhibitors. These luminal, ileum‐targeted agents block bile acid reabsorption, thereby increasing fecal bile acid excretion and effectively reducing the systemic bile acid pool to relieve pruritus. However, this pharmacological blockade also attenuates the intestinal farnesoid X receptor (FXR)–fibroblast growth factor 19 (FGF19) feedback loop, leading to a compensatory increase in hepatic bile acid synthesis. Consequently, the clinical efficacy and safety of IBAT inhibitors are heavily dependent on a sufficiently preserved enterohepatic bile flow and canalicular export capacity. When luminal bile acid delivery is impaired, therapeutic benefits diminish, and the unchecked compensatory synthesis may contribute to hepatocyte stress and elevated transaminases. Thus, optimizing the use of these therapies will require a shift from broad disease‐label indications toward precision, genotype‐ and physiology‐informed patient selection, utilizing non‐invasive biomarkers to assess target engagement and guide clinical management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dipartimento Interdisciplinare di Medicina, Università degli Studi Di Bari, Bari, Italy.
- National Institute for Biostructure and Biosystems (INBB), Roma, Italy.
ORCID-Profile: Ersilia Di Buduo, Antonio Moschetta
Förderung
- Ministero della Salute, Piano Sviluppo e Coesione Salute - FSC 2014-2020 - Traiettoria 3
- Incentivi Fondo per lo sviluppo di tecnologie e applicazioni di intelligenza artificiale, blockchain e Internet of Things
- European Union-Next Generation EU-PNRR M6C2
- European Union, European Regional Development Funds (E.R.D.F), National Funds of Greece and Italy
- Ministero della Salute, Bando Ricerca Finalizzata 2024
- Ministero della Salute
- European Commission
Zitieren
APA
Di Buduo, E., Crudele, L., Cantatore, S., & Moschetta, A. (2026). Ileal bile acid transporter inhibitors. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70692
Vancouver
Di Buduo E, Crudele L, Cantatore S, Moschetta A. Ileal bile acid transporter inhibitors. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70692
BibTeX
@article{DiBuduo2026,
author = {Di Buduo, Ersilia and Crudele, Lucilla and Cantatore, Salvatore and Moschetta, Antonio},
title = {Ileal bile acid transporter inhibitors},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
doi = {10.1002/jpn3.70692}
}
EUVIMED